Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 118600229 | 11860022 | 9 | F | 201307 | 20160816 | 20151222 | 20160824 | EXP | ID-BAYER-2015-360619 | BAYER | 65.00 | YR | E | M | Y | 0.00000 | 20160824 | OT | ID | ID |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 118600229 | 11860022 | 1 | PS | NEXAVAR | SORAFENIB | 1 | Oral | UNK MG, UNK | 21923 | FILM-COATED TABLET | |||||||||
| 118600229 | 11860022 | 2 | SS | NEXAVAR | SORAFENIB | 1 | Oral | 200 MG, BID | 21923 | 200 | MG | FILM-COATED TABLET | BID | ||||||
| 118600229 | 11860022 | 3 | SS | NEXAVAR | SORAFENIB | 1 | Oral | 400 MG, QOD | 21923 | 400 | MG | FILM-COATED TABLET | |||||||
| 118600229 | 11860022 | 4 | SS | NEXAVAR | SORAFENIB | 1 | Oral | 400 MG, QD | 21923 | 400 | MG | FILM-COATED TABLET | QD | ||||||
| 118600229 | 11860022 | 5 | SS | NEXAVAR | SORAFENIB | 1 | Oral | 400 MG, QD (3 DAYS TOOK FOLLOWED WITH 2 DAYS OFF) | 21923 | 400 | MG | FILM-COATED TABLET | QD | ||||||
| 118600229 | 11860022 | 6 | SS | NEXAVAR | SORAFENIB | 1 | Oral | 400 MG, QD (DAILY) | 21923 | 400 | MG | FILM-COATED TABLET | QD | ||||||
| 118600229 | 11860022 | 7 | SS | NEXAVAR | SORAFENIB | 1 | Oral | 400 MG, QOD (2X200 MG EOD) | 21923 | 400 | MG | FILM-COATED TABLET | QOD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 118600229 | 11860022 | 1 | Hepatocellular carcinoma |
| 118600229 | 11860022 | 2 | Hepatocellular carcinoma |
| 118600229 | 11860022 | 3 | Hepatocellular carcinoma |
| 118600229 | 11860022 | 4 | Hepatocellular carcinoma |
| 118600229 | 11860022 | 5 | Hepatocellular carcinoma |
| 118600229 | 11860022 | 6 | Hepatocellular carcinoma |
| 118600229 | 11860022 | 7 | Hepatocellular carcinoma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 118600229 | 11860022 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 118600229 | 11860022 | Abasia | |
| 118600229 | 11860022 | Alpha 1 foetoprotein increased | |
| 118600229 | 11860022 | Aphonia | |
| 118600229 | 11860022 | Arthralgia | |
| 118600229 | 11860022 | Blister | |
| 118600229 | 11860022 | Diarrhoea | |
| 118600229 | 11860022 | Dry mouth | |
| 118600229 | 11860022 | Dry throat | |
| 118600229 | 11860022 | Eating disorder | |
| 118600229 | 11860022 | Feeling hot | |
| 118600229 | 11860022 | Frequent bowel movements | |
| 118600229 | 11860022 | Gait disturbance | |
| 118600229 | 11860022 | Gingival pain | |
| 118600229 | 11860022 | Hepatic neoplasm | |
| 118600229 | 11860022 | Increased tendency to bruise | |
| 118600229 | 11860022 | Myalgia | |
| 118600229 | 11860022 | Oropharyngeal pain | |
| 118600229 | 11860022 | Pain in extremity | |
| 118600229 | 11860022 | Palmar-plantar erythrodysaesthesia syndrome | |
| 118600229 | 11860022 | Pruritus | |
| 118600229 | 11860022 | Toothache |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 118600229 | 11860022 | 1 | 201104 | 201203 | 0 | |
| 118600229 | 11860022 | 2 | 201306 | 0 | ||
| 118600229 | 11860022 | 3 | 201306 | 0 | ||
| 118600229 | 11860022 | 6 | 201605 | 2016 | 0 | |
| 118600229 | 11860022 | 7 | 20160813 | 0 |